



ALX Oncology to Host Virtual R&D Day on March 5, 2025

February 18, 2025

Company leadership and external key opinion leaders to highlight clinical program progress and provide business and financial updates

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that it will host a virtual Research and Development (R&D) Day webcast on Wednesday, March 5, 2025, at 6:00 a.m. PT/9:00 a.m. ET. The virtual webcast event will focus on information and updates related to the company's pipeline, lead investigational CD47-blocker evorpacept, as well as business and financial updates.

R&D Day Webcast Information

The ALX Oncology virtual R&D Day will be webcast live and a replay will be available after the event by visiting the "Investors" section of [ALX Oncology's website](#) and selecting "Events and Presentations."

Date & Time: Wednesday, March 5, 2025, 6:00 a.m. PT/9:00 a.m. ET

Webcast Access: <https://edge.media-server.com/mmc/p/yfucf8t5>

About ALX Oncology

ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives. ALX Oncology's lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn [@ALX Oncology](#).

Investor Relations Contact:

Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com

Media Contact:

Audra Friis, Sam Brown, Inc.
audrafriis@sambrown.com
(917) 519-9577